

INDEVUS PHARMACEUTICALS INC
Form 8-K
January 06, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2009

Indevus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-18728
(Commission File Number)

33 Hayden Avenue

04-3047911
(IRS Employer
Identification Number)

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 8-K

Lexington, Ma 02421-7966

(Address of principal executive offices)

Registrant's telephone number, including area code:

(781-861-8444)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 1 Registrant's Business and Operations

**Item 1.01 Entry into a Material Definitive Agreement.
Agreement and Plan of Merger**

On January 5, 2009, Indevus Pharmaceuticals, Inc., a Delaware corporation (the Company), entered into an Agreement and Plan of Merger (the Merger Agreement) with Endo Pharmaceuticals Holdings Inc., a Delaware corporation (Endo) and BTB Purchaser Inc., a Delaware corporation and wholly-owned subsidiary of Endo (Purchaser), pursuant to which Endo will acquire the Company.

Pursuant to the terms of the Merger Agreement, and subject to the conditions thereof, Endo (through Purchaser) has agreed to commence a cash tender offer (the Offer) to purchase all of the issued and outstanding shares of the common stock, par value \$0.001 per share, of the Company (the Shares) at a price of \$4.50 per Share, net to the seller in cash (less any required withholding taxes and without interest), plus contractual rights to receive up to an additional \$3.00 per Share in contingent cash consideration payments (the Offer Price), which will be payable upon certain drug approval and sales milestones being achieved. The Offer will expire at 5 p.m. New York time on the 45th day following and including the commencement date, unless extended in accordance with the terms of the Merger Agreement and the applicable rules and regulations of the Securities and Exchange Commission (such time, the Offer Closing).

The Offer, if successful, will be followed by a merger (the Merger) of Purchaser with and into the Company, with the Company as the surviving corporation and a wholly owned subsidiary of Endo. In the Merger, any Shares not tendered into the Offer, other than Shares held by the Company, Endo, Purchaser or shareholders who have validly exercised their appraisal rights under the General Corporate Law of the State of Delaware, will be cancelled and automatically converted into the right to receive the same per share consideration paid to shareholders in the Offer.

The consummation of the Offer is subject to the satisfaction or waiver of certain conditions, including: (i) a minimum of the majority of outstanding Shares on a fully diluted basis having been tendered into the Offer, (ii) the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act, (iii) the absence of litigation or governmental action challenging or seeking to prohibit the Offer or the Merger, (iv) there not having been a Material Adverse Effect with respect to the Company, and (v) other customary conditions.

Pursuant to the Merger Agreement and subject to certain exceptions, the Company granted to Purchaser an irrevocable option (the Top-up Option) to purchase, at a per Share price equal to the Offer Price, newly issued Shares in an amount up to the lowest number of Shares that, when added to the number of Shares owned by Purchaser at the time of exercise of the Top-Up Option, will constitute one Share more than 90% of the total Shares outstanding on a fully diluted basis. The price per share to be paid for the Top-Up shares will be the Offer Price.

The Merger Agreement contains certain termination rights of Endo and the Company and provides that, upon the termination of the Merger Agreement under particular circumstances, the Company would be required to pay Endo a termination fee equal to \$20 million.

Concurrently with the execution and delivery of the Merger Agreement, Endo and Purchaser entered into an agreement with each of Glenn L. Cooper, M.D., Michael W. Rogers, Noah D. Beerman, Mark S. Butler, Bobby W. Sandage, Jr., Ph.D, Malcolm Morville, Ph.D, and Sanders Morris Harris (an entity that controls certain stockholders of the Company that are affiliated with James C. Gale, a director of the Company), pursuant to which each of them has irrevocably agreed to tender the shares of Company common stock beneficially owned by such executive officer or director in the Offer.

The foregoing description of the Offer, the Merger and the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is attached hereto as Exhibit 2.1 and incorporated herein by reference.

The Merger Agreement has been included to provide investors with information regarding its terms. It is not intended to provide any other factual information about Endo and the Company. The Merger Agreement contains representations and warranties that each of Endo and the Company made to the other. The assertions embodied in those representations and warranties are qualified by information in confidential disclosure schedules that the parties have exchanged in connection with signing the Merger Agreement. The disclosure schedules contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Merger Agreement. Accordingly, investors should not rely on the representations and warranties as characterizations of the actual state of facts at the time they were made or otherwise.

Contingent Cash Consideration Agreements

Pursuant to the Merger Agreement, prior to the Offer Closing, Endo will enter into two separate agreements with American Stock Transfer & Trust Company (the Paying Agent), for the purpose of establishing the terms, policies and procedures by which those stockholders entitled to any of the Contingent Cash Consideration Payments (as defined below) will be paid. In accordance with 21 C.F.R. Part 314, and all supplements filed pursuant to the requirements of FDA, the Company intends to file certain new drug applications for the right to market and sell (i) a certain octreotide implant currently under development for the treatment of acromegaly and carcinoid syndrome, which is a soft, flexible 6-month hydrogel implant based on the patented HYDRON Polymer Technology that delivers octreotide, a somatostatin analogue (such octreotide implant, Octreotide and such new drug application, the Octreotide NDA) and (ii) a certain long-acting intramuscular depot injection of testosterone undecanoate currently under development for the treatment of male hypogonadism (such injection, NEBID[®] and such new drug application, the NEBID[®]NDA or, together with the Octreotide NDA, the NDAs).

In the event that the Company receives an approval letter from the FDA with respect to the NEBID[®] NDA on or before the third anniversary of the time at which we purchase Shares in the Offer (such time, the Offer Closing), then Purchaser will, subject to the terms described below, (i) pay an additional \$2.00 per Share to stockholders of the Company whose Shares are accepted for payment in connection with the Offer, if such approval letter grants the right to market and sell NEBID[®] immediately and provides labeling for NEBID[®] that does not contain a boxed warning (as defined in 21 C.F.R. 201.57(c)(1)) (such approval letter, the NEBID[®]With Label Approval and such payment, the NEBID[®]With Label Approval Contingent Cash Consideration Payment) or alternatively, (ii) pay an additional \$1.00 per Share to stockholders of the Company whose Shares are accepted for payment in connection with the Offer, if such approval letter grants the right to market and sell NEBID[®] immediately and provides labeling for NEBID[®] that contains a boxed warning (as defined in 21 C.F.R. 201.57(c)(1)) (such approval letter, the NEBID[®]Without Label Approval and such payment, the NEBID[®]Without Label Contingent Cash Consideration Payment). In the event that either a NEBID[®]With Label Approval or a NEBID[®]Without Label Approval has not been obtained prior to the third anniversary of the Effective Time, then Purchaser will not pay, and tendering stockholders shall not receive, the NEBID[®]With Label Contingent Cash Consideration Payment or the NEBID[®]Without Label Contingent Cash Consideration Payment, as applicable.

A boxed warning is ordinarily used to highlight for prescribers one of the following situations: (1) there is an adverse reaction so serious in proportion to the potential benefit from the drug (e.g., a fatal, life-threatening or permanently disabling adverse reaction) that it is essential that it be considered in assessing the risks and benefits of using a drug, (2) there is a serious adverse reaction that can be prevented or reduced in frequency or severity by appropriate use of the drug (e.g., patient selection, careful monitoring, avoiding certain concomitant therapy, addition of another drug or managing patients in a specific manner, avoiding use in a specific clinical situation), or (3) the FDA approved the drug with restrictions to assure safe use because the FDA concluded that the drug can be safely used only if distribution or use is restricted. A boxed warning can also be used in other situations to highlight warning information that is especially important to the prescriber.

Further, in the event that the NEBID[®]Without Label Approval is received and subsequently, Endo and its subsidiaries publicly report audited financial statements which reflect that Net Sales (as defined below) of NEBID[®] of at least \$125,000,000, on or prior to the fifth anniversary of the date of the first commercial sale of NEBID[®] (such event, the NEBID[®]Net Sales Event), then Purchaser will, subject to the terms described below, pay an additional \$1.00 per Share to stockholders of the Company whose Shares are accepted for payment in connection with the Offer (such payment, the NEBID[®]Net Sales Contingent Cash Consideration Payment and, together with the NEBID[®]Without Label Approval Contingent Cash Consideration Payment, the NEBID[®]

With Label Approval Contingent Cash Consideration Payment and the Ocreotide Contingent Cash Consideration Payment, the Contingent Cash Consideration Payments). In the event that the NEBIDO® Net Sales Event does not occur prior to the fifth anniversary of the date of the first commercial sale of NEBIDO®, then Purchaser will not pay, and tendering stockholders shall not receive, the NEBIDO® Net Sales Contingent Cash Consideration Payment.

Net Sales means, with respect to NEBIDO®, the gross amount invoiced by or on behalf of Endo or its affiliates, licensees or sublicensees for NEBIDO® sold to third parties other than licensees or sublicensees in bona fide, arm's-length transactions, less the following deductions, determined in accordance with Endo's standard accounting methods as generally and consistently applied by Endo, to the extent included in the gross invoiced sales price of the product or otherwise directly paid or incurred by Endo, its affiliates, licensees or sublicensees acting on its behalf with respect to the sale of such product:

- (1) normal and customary trade and quantity discounts actually allowed and properly taken directly with respect to sales of the product;
- (2) amounts repaid or credited by reasons of defects, recalls, returns, rebates and allowances of goods or because of retroactive price reductions specifically identifiable to the product;
- (3) chargebacks, rebates (or the equivalent thereof) and other amounts paid on sale or dispensing of the product;
- (4) rebates (or the equivalent thereof) and administrative fees paid to medical healthcare organizations, to group purchasing organizations or to trade customers in line with approved contract terms or other normal and customary understandings and arrangements;
- (5) amounts payable resulting from governmental (or agency thereof) mandated rebate programs or chargeback programs;
- (6) tariffs, duties, excise, sales, value-added and other taxes (other than taxes based on income) and charges of Governmental Authorities;
- (7) cash discounts for timely payment;
- (8) rebates paid to wholesalers for inventory management programs;
- (9) amounts repaid or credited or provisions made for uncollectible amounts on previously sold products; and
- (10) required distribution commissions and fees (such as fees related to services provided pursuant to distribution service agreements with major wholesalers) payable to any third party providing distribution services to Endo so long as such commissions and fees are consistent with the distribution commissions and fees payable in respect to other branded prescription products commercialized by Endo;

all as determined in accordance with Endo's usual and customary accounting methods, which shall be in accordance with U.S. Generally Accepted Accounting Principles; or in accordance with International Financial Reporting Standards (IFRS), should Endo be required to, or elect to maintain records and books of accounts in accordance with IFRS. Sales from Endo to its affiliates, licensees or sublicensees shall be disregarded for purposes of calculating Net Sales. Any of the items set forth above that would otherwise be deducted from the invoice price in the calculation of Net Sales but which are charged to third parties shall not be deducted from the invoice price in the calculation of Net Sales. Further: (1) In the case of any sale or other disposal of a product between or among Endo and its affiliates, licensees and sublicensees, for resale, Net Sales shall be calculated as above only on the value charged or invoiced on the first arm's-length sale thereafter to a third party; (2) In the case of any sale which is not invoiced or is delivered before invoice, Net Sales shall be calculated at the time of shipment or when the product is paid for, if paid for before shipment or invoice; and (3) In the case of any sale or other disposal for value, such as barter or counter-trade, of any product, or part thereof, other than in an arm's-length transaction exclusively for money and excluding any patient assistance programs, Net Sales shall be calculated as above on the value of the non-cash consideration received or the fair market price (if higher) of the product in the country of sale or disposal.

Endo has agreed to deposit \$175,000,000 in cash with a paying agent pursuant to the terms of the NEBIDO[®] Contingent Cash Consideration Agreement, which amount is approximately equal to the aggregate amount payable to the Company stockholders and others pursuant to the Merger Agreement if the NEBIDO[®] approval is obtained and is not subject to a boxed warning label (described above) by the FDA, and will be paid to the Company stockholders and others pursuant to the Merger Agreement, under the terms of the NEBIDO[®] Contingent Cash Consideration Agreement.

Similarly, in the event that an approval letter from the FDA is received with respect to the Octreotide NDA (such approval letter, the Octreotide Approval) on or before the fourth anniversary of the Offer Closing, then Purchaser will, subject to the terms described below, pay an additional \$1.00 per Share to stockholders of the Company whose Shares are accepted for payment in connection with the Offer (such payment, the Octreotide Contingent Cash Consideration Payment). In the event that an Octreotide Approval has not been obtained prior to the fourth anniversary of the Offer Closing, then Purchaser will not pay, and tendering stockholders shall not receive, the Octreotide Contingent Cash Consideration Payment.

Pursuant to the Nebido Contingent Cash Consideration Agreement, within five business days of the NEBIDO[®] With-Label Approval, the NEBIDO[®] Without-Label Approval or NEBIDO[®] Net Sales Event, as applicable, Endo will provide the Paying Agent with a certificate stating that such approval or event has occurred and the payment date with respect on which such Contingent Cash Consideration Payment shall be made, which shall be within five business days of the date of such certificate. The Paying Agent will pay the applicable Contingent Cash Consideration Payment to the stockholders who tendered their Shares in the Offer or who are entitled to receive the Merger Consideration (as defined in the Merger Agreement) on the payment date specified in the certificate. Such Contingent Cash Consideration Payment will be equal to (i) \$2.00, in the case of the NEBIDO[®] With Label Approval, (ii) \$1.00, in the case of the NEBIDO[®] Without Label Approval or (iii) \$1.00, in the case of the NEBIDO[®] Net Sales Event. Endo has agreed to deposit \$175,000,000 in cash with a paying agent pursuant to the terms of the NEBIDO[®] Contingent Cash Consideration Agreement, which amount is equal to the aggregate amount payable to the Company stockholders if the NEBIDO[®] approval is obtained and is not subject to a boxed warning label (described above) by the FDA, and will be paid to the Company stockholders under the terms of the NEBIDO[®] Contingent Cash Consideration Agreement. The foregoing summary is qualified in its entirety by reference to the complete text of the form of NEBIDO[®] Contingent Cash Consideration Agreement, which is attached hereto as Exhibit 99.2, and which is incorporated herein by reference.

Pursuant to the Octreotide Contingent Cash Consideration Agreement, within five business days of the Octreotide Approval, Endo will provide the Paying Agent with a certificate stating that such approval or event has occurred and the payment date with respect on which the applicable \$1.00 Contingent Cash Consideration Payment shall be made, which shall be within five business days of the date of such certificate. The Paying Agent will pay the \$1.00 Contingent Cash Consideration Payment to the stockholders who tendered their Shares in the Offer or who are entitled to receive the Merger Consideration (as defined in the Merger Agreement) on the payment date specified in the certificate. The foregoing summary is qualified in its entirety by reference to the complete text of the form of Octreotide Contingent Cash Consideration Agreement, which is attached hereto as Exhibit 99.3, and which is incorporated herein by reference.

Stockholder Tender Agreements

In connection with the Merger Agreement, Endo and Purchaser have entered into certain Stockholder Tender Agreements with the directors, executive officers and affiliates of one of the directors that own Shares, pursuant to which, among other things, each such director, executive officer and affiliates agreed to irrevocably tender (and deliver any certificates evidencing) its Shares, or cause its Shares to be irrevocably tendered, into the Offer promptly following, and in any event no later than the fifth business day following, the commencement of the Offer. Such stockholders are: Glenn L. Cooper, M.D., Malcolm Morville, Ph.D., Noah D. Beerman, Mark S. Butler, Michael W. Rogers, Bobby W. Sandage, Jr., Ph.D. and certain stockholders controlled by Sanders Morris Harris, an entity affiliated with James C. Gale, a director of the Company. A copy of the Form of Stockholder Tender Agreement is furnished herewith as Exhibit 99.4 and is incorporated in this report by reference.

Section 8 Other Events

Item 8.01 Other Events.

On January 5, 2009, the Company issued a press release regarding the execution of the Merger Agreement. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated in this report by reference.

Section 9 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Document Description
2.1	Agreement and Plan of Merger, dated as of January 5, 2009, by and among Endo Pharmaceuticals Holdings Inc., BTB Purchaser Inc. and Indevus Pharmaceuticals, Inc.
99.1	Press Release issued on January 5, 2009
99.2	Form of NEBIDO® Contingent Cash Consideration Agreement by and among Endo Pharmaceuticals Holdings Inc. and American Stock Transfer and Trust Company
99.3	Form of Octreotide Contingent Cash Consideration Agreement by and among Endo Pharmaceuticals Holdings Inc. and American Stock Transfer and Trust Company
99.4	Form of Stockholder Tender Agreement

Additional Information

This Current Report on Form 8-K is not a recommendation, an offer to purchase or a solicitation of an offer to sell shares of the Company's common stock. Purchaser has not commenced the Offer for shares of the Company's stock described in this communication.

Upon commencement of the Offer, Purchaser and Endo will file with the Securities and Exchange Commission a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. Following commencement of the Offer, the Company will file with the Securities and Exchange Commission a solicitation/recommendation statement on Schedule 14D-9. Shareholders should read the offer to purchase and solicitation/recommendation statement and the tender offer statement on Schedule TO and related exhibits as they will contain important information about the Offer. Stockholders of the Company will be able to obtain a free copy of these documents (when they become available) and other documents filed by the Company or Endo with the Securities and Exchange Commission (the "SEC") at the website maintained by the SEC at www.sec.gov.

In addition, the Company's stockholders will be able to obtain a free copy of these documents (when they become available) from the Company by directing a request to Indevus Pharmaceuticals, Inc., Attention: General Counsel, 33 Hayden Avenue, Lexington, Massachusetts 02421-7966 or by phone at (781) 861-8444.

Forward Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on current expectations of future events. Also, statements including words such as believes, expects, anticipates, intends, estimates, plan, will, may or similar expressions are forward-looking statements. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Endo's and Indevus' expectations and projections. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act and

receipt of certain other regulatory approvals for the transaction, the tender of a majority of the outstanding shares of common stock of Indevus, and the possibility that the transaction will not be completed; general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Endo's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2007, filed with the U.S. Securities and Exchange Commission (SEC) on April 29, 2008, and its Quarterly Report on Form 10-Q/A for the fiscal quarter ended September 30, 2008, filed with the SEC on December 12, 2008 and Indevus' Form Annual Report on Form 10-K as filed with the SEC on December 11, 2008. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.endo.com, www.indevus.com or on request from Endo or Indevus. Indevus does not undertake to update any forward looking statements as a result of new information or future events or developments.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INDEVUS PHARMACEUTICALS, INC.

Dated: January 6, 2009

By: /s/ Glenn L. Cooper, M.D.
Glenn L. Cooper, M.D.
Chief Executive Officer

and Chairman of the Board of Directors

Exhibit List

Exhibit No.	Document Description
2.1	Agreement and Plan of Merger, dated as of January 5, 2009, by and among Endo Pharmaceuticals Holdings Inc., BTB Purchaser Inc. and Indevus Pharmaceuticals, Inc.
99.1	Press Release issued on January 5, 2009
99.2	Form of NEBIDO® Contingent Cash Consideration Agreement by and among Endo Pharmaceuticals Holdings Inc. and American Stock Transfer and Trust Company
99.3	Form of Octreotide Contingent Cash Consideration Agreement by and among Endo Pharmaceuticals Holdings Inc. and American Stock Transfer and Trust Company
99.4	Form of Stockholder Tender Agreement